Projects per year
Personal profile
Personal profile
Dr. Li finished his medical school at Beijing Medical University and his graduate school at Penn State. He had his postdoctoral training at Stanford University before joining the Research Institute in late 2017.
Research interests
Dr. Li's research interest includes 1) non-genetic mechanisms of therapeutic resistance, and 2) rational combination therapy. Dr. Li's lab utilizes both experimental and computational approaches to study cancer biology and therapeutics.
Research Area Keywords
- Cancer
Free-text keywords
- Chemoresistance
- Combination therapy
- Senescence & Dormancy
- CRISPR library screening
- Proteomics in oncology
Fingerprint
Dive into the research topics where Yulin Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Functional roles of mTOR in tumor persistence
Li, Y. (PI)
4/4/24 → 3/31/29
Project: Federal Funding Agencies
-
-
Dissecting the role of the mTOR pathway in tumor persistence
Li, Y. (PI)
1/1/24 → 1/31/24
Project: Non Profit
-
Rational Combination Therapy for Aggressive Double-Hit Lymphoma
Li, Y. (PI)
8/31/20 → 8/31/24
Project: State
-
The Role of Suv420h1 Histone Methyltransferase in MYC-Driven Tumorigenesis
Li, Y. (PI)
9/8/17 → 8/31/21
Project: Federal Funding Agencies
-
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma
Deutzmann, A., Sullivan, D. K., Dhanasekaran, R., Li, W., Chen, X., Tong, L., Mahauad-Fernandez, W. D., Bell, J., Mosley, A., Koehler, A. N., Li, Y. & Felsher, D. W., Feb 1 2024, In: Nature Communications. 15, 1, p. 963 963.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters
Liu, Y., Azizian, N. G., Sullivan, D. K. & Li, Y., Nov 17 2022, In: Nature Communications. 7047.Research output: Contribution to journal › Article › peer-review
Open Access -
mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters
Liu, Y., Azizian, N. G., Sullivan, D. K. & Li, Y., Dec 2022, In: Nature Communications. 13, 1, 7047.Research output: Contribution to journal › Article › peer-review
Open Access20 Scopus citations -
mTOR is a major determinant of chemosensitivity
Liu, Y., Azizian, N. G., Sullivan, D. K. & Li, Y., Jan 21 2022, (Unpublished) In: bioRxiv.Research output: Contribution to journal › Article
-
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y. & Li, Y., Mar 6 2021, In: BMC Cancer. 21, 1, p. 237 13 p., 237.Research output: Contribution to journal › Article › peer-review
Open Access17 Scopus citations
Prizes
-
American Cancer Society Research Scholar Award
Li, Y. (Recipient), Oct 1 2023
Prize: Prize (including medals and awards)
-
Houston Methodist Neal Cancer Center Innovation Award
Li, Y. (Recipient), Aug 22 2023
Prize: Prize (including medals and awards)